Knee gel injection trial pulled before it began

NCT ID NCT06839222

Terminated Symptom relief Sponsor: Allegro NV/SA Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test whether a new gel called Hydrogel OA 2% could safely relieve knee osteoarthritis pain better than a standard treatment. It planned to enroll adults with knee OA and give them one injection, then track side effects and symptom improvement for 26 weeks. However, the trial was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydrogel OA 2% (a gel made from bovine gelatin and cellulose nanocrystals)
What this could lead to: If it had worked, this could have pointed toward a new injection to ease knee pain and improve function in osteoarthritis.
What could go wrong: The trial was withdrawn before enrolling anyone, so no data on safety or effectiveness exist. Early-stage device studies often fail to show benefit or may have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS (KNEE OA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Knee Injuries osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRITIS (KNEE OA)

Contacts and locations

Locations

AZ DELTA

Roeselare, Belgium
AZ Sint Jan Brugge

Bruges, Belgium
CHU Liège

Liège, Belgium
More Institute

Antwerp, Belgium
UZ Antwerpen

Edegem, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.